← board
ZEOX
distress 2/10 · well-funded / low risk$1.77+5%today-39% from 52w high
Lead: hair loss
Revenue
pre-revenue
Liquidity
$2M
Runway
1.6 yrs
Shares 1y
+20%
Price & events
-34.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.7%
1D
-8.8%
1W
+6.6%
1M
-4.2%
3M
-34.2%
6M
-13.2%
1Y
-24.0%
2Y
-91.5%
5Y
-94.3%
All
Overview
- Market Cap
- $13.87M
- Volume
- 400
- 52 Week Range
- $1.25 – $2.89
- Total Shares
- 7.84M
- Float Shares
- 4.45M
- % Held by Insiders
- 35.61%
- % Held by Institutions
- 0.00%
- RVOL
- 0.11x
- Beta
- 1.65
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 7
- 2026-04-09partnershipZEO entered into an MOU with Regen Therapy for an exclusive scientific and biologics strategic collaboration, positioning ZEO as the core supplier of advanced biologic therapeutics.SEC 8-K
- April 9, 2026conferencedata presentationsecondaryZEO will lead a full-day Masterclass on regenerative and longevity medicine at Longevity SpringFest 2026.SEC 8-K
- 2026-03-31partnershipZEO becomes official educational partner for regenerative medicine with A4M at Longevity SpringFest 2026.SEC 8-K
- 2026-01-07partnershipComprehensive strategic partnership among Zeo, Cytora, and Made Scientific to advance and commercialize Cytora's allogeneic oral mucosal stem cell therapy in the U.S.SEC 8-K
- 2024-12-31partnershipZofin · Strategic partnership with Physicians Group, LLC for clinical trials and patient access.SEC 8-K
- 2024-12-01partnershipZEO HAIR GROW · Launch of ZEO HAIR GROW powered by Exotropin with Exotropin LLC.SEC 8-K
- November 15, 2024conferencedata presentationsecondaryZEO HAIR GROW · Presentation at Medical Aesthetics Professionals meeting in Scottsdale, AZ introducing ZEO HAIR GROW systemSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — hair loss
- MANEVeradermics, Inc$4.6B · D2
Recent news
- 2026-07-21Zeo ScientifiX Expands South Florida Regenerative Medicine Presence - TipRanks
- 2026-07-21ZEO ScientifiX Strengthens South Florida's Growing Biotechnology Ecosystem Through Regenerative Medicine Innovation - ACCESS Newswire
- 2026-07-13Price to sales forward of Zeo ScientifiX Inc. – OTC:ZEOX - TradingView
- 2026-07-12Price to earnings forward of Zeo ScientifiX Inc. – OTC:ZEOX - TradingView
- 2026-07-08ZEO ScientifiX Reports Strong Revenue Growth for Three Months and Six Months Ended April 30, 2026 - marketscreener.com
- 2026-07-01ZEO ScientifiX to Host Live Educational Webinar for Healthcare Professionals Exploring the Southeast Regenerative Medicine Revolution - ACCESS Newswire
- 2026-04-09Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics--Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX - PR Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.